| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Hydroxy-PEG4-t-butyl ester functions as a linker in bioconjugation applications. The hydrophilic PEG spacer increases solubility in aqueous media. The hydroxyl group enables further derivatization or replacement with other reactive functional groups. The t-butyl ester provides robust protection for the terminal carboxylic acid and can be deprotected under acidic conditions to reveal the free carboxyl group for amine coupling.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
Hydroxy-PEG4-t-butyl ester is not typically used in pharmacological activity assays. Its activity is related to its utility as a chemical linker. Its properties, such as solubility and reactivity, are characterized for its use in bioconjugation and drug delivery applications. It is used in the synthesis of ADCs. |
| ln Vivo |
Hydroxy-PEG4-t-butyl ester is used in the synthesis of antibody-drug conjugates (ADCs) for research purposes. It is not a drug itself and does not have direct in vivo pharmacological activity. Its effects are observed in the context of the conjugates it helps to create.
|
| Enzyme Assay |
Hydroxy-PEG4-t-butyl ester does not have a typical enzyme/receptor binding assay. Its properties are assessed based on its chemical and physical characteristics, such as purity, molecular weight, and reactivity. It is not used in standard pharmacological binding assays.
|
| Cell Assay |
Hydroxy-PEG4-t-butyl ester is not typically used in cell-based assays. Its applications are primarily in chemical synthesis and bioconjugation. The compound's effects on cells are not a primary focus of study, as it is not intended for biological or therapeutic use as a standalone compound.
|
| Animal Protocol |
Hydroxy-PEG4-t-butyl ester is not used in animal experiments for pharmacological purposes. Its effects are studied in the context of chemical synthesis and bioconjugation. Animal studies are not relevant to its primary applications as a linker.
|
| ADME/Pharmacokinetics |
Hydroxy-PEG4-t-butyl ester has a molecular weight of 322.40 g/mol and a molecular formula of C15H30O7. It is a liquid at room temperature. It is soluble in water and organic solvents. It is typically stored at -20°C for long-term stability. Its purity is typically ≥95%.
|
| Toxicity/Toxicokinetics |
Hydroxy-PEG4-t-butyl ester is a chemical intermediate that is not intended for human use. Its toxicological profile is not extensively characterized in the available literature. Standard safety precautions should be followed when handling this compound in a laboratory setting.
|
| References | |
| Additional Infomation |
Hydroxy-PEG4-t-butyl ester is a PEG linker containing a hydroxyl group and a t-butyl ester, used in the synthesis of antibody-drug conjugates (ADCs). It is a heterobifunctional PEG linker with orthogonal protecting groups. The compound is available from various chemical suppliers for research and development purposes.
|
| Molecular Formula |
C15H30O7
|
|---|---|
| Molecular Weight |
322.3945
|
| Exact Mass |
322.199
|
| CAS # |
518044-32-1
|
| Related CAS # |
518044-32-1;
|
| PubChem CID |
11174684
|
| Appearance |
Colorless to light yellow liquid（Density：1.04746 g/cm3）
|
| LogP |
0.776
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
22
|
| Complexity |
263
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])O[H])=O)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
FJRDXEGYAVAMLB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H30O7/c1-15(2,3)22-14(17)4-6-18-8-10-20-12-13-21-11-9-19-7-5-16/h16H,4-13H2,1-3H3
|
| Chemical Name |
tert-butyl 3-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1018 mL | 15.5092 mL | 31.0183 mL | |
| 5 mM | 0.6204 mL | 3.1018 mL | 6.2037 mL | |
| 10 mM | 0.3102 mL | 1.5509 mL | 3.1018 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA